FemTech Company Announces Path to Expand to Australia after the successful launch in the US.
MOUNTAIN VIEW, CA., November 14, 2023 /PRNewswire/ — Revelle Aestheticsa VC-backed FemTech Silicon Valley company, today announced that Avéli®, its US FDA-cleared device for long-term reduction in the appearance of cellulite, has received its first international approval in Australiaone of the biggest bargains for cellulite out the United States.
“Cellulite is one of the most common skin conditions, affecting up to 90% of women1 Worldwide. And much like inside the United Statesis a common aesthetic concern in Australia which can affect the self-esteem of those who are bothered by it and who cannot find an effective solution,” he said Caroline Van Hove, President & CEO of Revelle Aesthetics. “With our Australian license, we are establishing our global footprint and look forward to bringing a real cellulite solution to women around the world.”
Cellulitis is any dimple or depression seen on the surface of the skin with a defined edge and is mainly caused by shortened or stiff septal bands under the skin that pull down the dermis, causing the dimpling effect. It is important to differentiate cellulite from loose skin (saggy skin) and fat (pockets of fat) because these conditions, although they often occur alongside cellulite, are treated quite differently.
Avéli is a first-of-its-kind device that delivers a substantial reduction in cellulite dimpling after just one in-office procedure, treating cellulite at its source. It is the only cellulite device that allows a provider to determine which of the septa under the skin are the culprits causing a dimple, allowing them to be highly targeted in their treatment approach.
Dr. Craig Layt, respected and qualified plastic and reconstructive surgeon from Southport, Australia, and past President of the Australasian Society of Aesthetic Plastic Surgeons, has extensive experience in the treatment of Avéli cellulite, having helped develop the Avéli device. Dr. Layt was the first to use the device clinically as the principal investigator for the initial safety and feasibility study and as an investigator in the pivotal clinical trial. “During our early work, we were able to determine that the diaphragms, although robust, are quite complex and highly mobile. This insight led to a device design that could very precisely target and release these complex diaphragms networks, but also confirm release in real-time,” said Dr. Light. “We have demonstrated that the Avéli device is safe and effective in providing long-term reduction of cellulite on the buttocks and thighs in a one-time, minimally invasive procedure.”
Since commercialization in the US, Avéli has exponentially grown its trained provider base, treated thousands of patients, and created hundreds of real-word before-and-after photos displayed on providers’ social channels showcasing Avéli’s impressive results.
“As we prepare our Australian go-to-market plan, we are committed to building on the scientific credibility and meaningful real-world results achieved by hundreds of specialist providers since its launch the United States and we look forward to replicating this success overseas,” he said Benjamin BishopChief Commercial Officer of Revelle Aesthetics.
For more information on the minimally invasive in-office cellulite solution2visit MyAveli.com and follow @aveli on Instagram.
ABOUT AESTHETIC REVELLE
Revelle Aesthetics is a Silicon Valley-based FemTech company focused on innovating smart solutions that address the root causes of women’s most vexing aesthetic concerns. The company is committed to developing precision technologies that deliver meaningful results for women and reliable results for doctors. Revelle Aesthetics’ first device, Avéli®, is FDA-approved and TGA-licensed for long-term reduction of the appearance of cellulite on the buttocks and thighs of adult females, as supported by clinical data demonstrating treatment benefits after one year follow-up. It was founded in 2018 and is based in Mountain View, CaliforniaRevelle Aesthetics is a privately held company backed by leading venture capital firms New Enterprise Associates and KCK Medtech. For more information visit RevelleAesthetics.com.
- Emanuele E. Cellulitis: advances in treatment: facts and controversies. Clin Dermatol. 2013? 31 (6): 725-30.
- Stevens WG, et al. Aesthet Surg J. 2023;43(4):455-466.
Media contact:
Sarah Mudge
smatz@revelleax.com
SOURCE Revelle Aesthetics
